VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 560 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2015. The put-call ratio across all filers is 2.18 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $103,000 | -99.9% | 7,688 | -25.4% | 0.03% | -34.1% |
| Q2 2017 | $178,000,000 | +97.8% | 10,303 | +6.2% | 0.04% | +76.0% |
| Q1 2017 | $90,000,000 | +55.2% | 9,703 | +143.1% | 0.02% | +150.0% |
| Q4 2016 | $58,000,000 | +62265.6% | 3,992 | +5.7% | 0.01% | -41.2% |
| Q3 2016 | $93,000 | +1062.5% | 3,775 | +792.4% | 0.02% | +466.7% |
| Q2 2016 | $8,000 | -11.1% | 423 | +21.6% | 0.00% | 0.0% |
| Q1 2016 | $9,000 | -89.5% | 348 | -59.0% | 0.00% | -90.6% |
| Q4 2015 | $86,000 | +132.4% | 848 | +305.7% | 0.03% | +146.2% |
| Q3 2015 | $37,000 | -72.6% | 209 | -65.7% | 0.01% | -72.3% |
| Q2 2015 | $135,000 | +11.6% | 610 | -0.7% | 0.05% | +20.5% |
| Q1 2015 | $121,000 | +61.3% | 614 | +17.4% | 0.04% | +56.0% |
| Q4 2014 | $75,000 | -6.2% | 523 | -14.1% | 0.02% | +56.2% |
| Q3 2014 | $80,000 | +73.9% | 609 | +42.0% | 0.02% | -33.3% |
| Q2 2014 | $46,000 | – | 429 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |